脱发10年吃巴瑞替尼片有用吗？

如果是自身免疫异常导致的脱发，比如自身免疫性疾病，脱发10年吃巴瑞替尼片有效果，能够激活毛囊细胞，刺激毛发生长，达到治疗斑秃、脱发的效果，效果比较好，但如果是其他原因导致，比如遗传、雄Hormones, etc., although baricitinib tablets can be taken, the therapeutic effect is not good and does not belong to the treatment of the cause. It is recommended that patients find out the cause and carry out targeted treatment to improve hair loss as soon as possible to avoid seriously affecting their personal image and increasing their mental and psychological burden. This may affect their quality of life in the long term.

Approved by the State Food and Drug Administration, it is the first and only innovative targeted drug in China for the systemic treatment of severe alopecia areata, with proven efficacy. Baricitinib is an oral, selective, reversible inhibitor of Janus kinases 1 and 2 that may interrupt cytokine signaling involved in the pathogenesis of alopecia areata.

What is alopecia areata

Alopecia areata, commonly known as ghost hair loss, is an autoimmune disease characterized by rapid hair loss on the scalp, eyebrows and eyelashes. The patient's local scalp hair follicles are more sensitive to androgens, and under the influence of mental factors, infectious factors, etc., the hair follicles on the top of the head become smaller and the hair becomes thinner, manifesting as baldness. If there are many normal hair follicles in the donor area and the scalp in the recipient area is basically normal, hair transplantation is possible.

The effect of baricitinib tablets in the treatment of alopecia areata

In two randomized, placebo-controlled Phase 3 trials, namely BRAVE-AA1 and BRAVE-AA2, patients were randomly assigned in a 3:2:2 ratio to receive once-daily doses of 4 mg baricitinib tablets, 2 mg baricitinib tablets, or placebo.

At Week 36, the estimated percentages of patients with a salt score of 20 or less were 38.8% in the 4 mg baricitinib group, 22.8% in the 2 mg baricitinib group, and 6.2% in the placebo group in BRAVE-AA1, and 35.9%, 19.4%, and 3.3%, respectively, in BRAVE-AA2.

In the BRAVE-AA1 group, there was a 32.6% difference between the 4 mg baricitinib tablets and the placebo group, and there was a 16.6% difference between the 2 mg baricitinib tablets and the placebo group.

In two phase 3 trials in patients with severe alopecia areata, baricitinib tablets produced better hair regrowth than placebo at 36 weeks.

baricitinib tablets

The recommended dose of baricitinib is 2 mg, taken once daily, on an empty stomach or with food, and at any time of the day. Baricitinib tablets are not recommended for patients with creatinine clearance <30 mL/minute and severe liver damage.

References:

King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, Hordinsky M, Dutronc Y, Wu WS, McCollam J, Chiasserini C, Yu G, Stanley S, Holzwarth K, DeLozier AM, Sinclair R; BRAVE-AA Investigators. Two Phase 3 Trials of Baricitinib for Alopecia Areata. N Engl J Med. 2022 May 5;386(18):1687-1699. doi: 10.1056/NEJMoa2110343. Epub 2022 Mar 26. PMID: 35334197.

Recommended related articles: